WHO at IAS2019
Who at IAS2019 High-level events

**DR CARISSA ETIENNE**
Director, Pan American Health Organization (PAHO) and Regional Director for the Americas of the World Health Organization (WHO).

**KEYNOTE SPEECH**
IAS2019 Opening session (SUPLO1)
Sunday 21 July, 19:30 - 20:30, Sala A

**DR REN MINGHUI**
Assistant Director-General, Universal Health Coverage/Communicable and Noncommunicable Diseases, WHO.

**OPENING REMARKS**
One year on: updated WHO guidelines on first-line treatment for people living with HIV (SUSA13)
Sunday 21 July, 14:45–16:45, Palacio de Valparaíso 1

**DR ANDREW BALL**
Director a.i, Department of HIV/Global Hepatitis Programme, WHO.

**CHAIR**
Political will to getting to zero infections (WESY06)
Wednesday 24 July, 16:30-17:30, Sala A

**DR RACHEL BAGGALEY**
Coordinator, Key Populations and Innovative Prevention, Department of HIV, WHO.

**ORGANIZER, SPEAKER**
PrEP and STIs: opportunities and challenges (SUSA07)
Sunday 21 July, 12:30–14:30, Palacio de Valparaíso 1

**DR MEG DOHERTY**
Coordinator, Treatment and Care, Department of HIV, WHO.

**ORGANIZER, SPEAKER**
One year on: updated WHO guidelines on first line treatment for people living with HIV (SUSA13)
Sunday 21 July, 14:45–16:45, Palacio de Valparaíso 1

**DR MASSIMO GHIDINELLI**
Chief, Unit of HIV, hepatitis, TB and Sexually transmitted infections, PAHO/WHO.

**CO-CHAIR**
New approaches to monitor HIV services and accelerate the response to HIV among men who have sex with men (MSM) and transgender women in Latin America (MOSA07)
Monday 22 July, 18:30–20:30, Palacio de Valparaíso 1
The meeting will provide a unique opportunity to bring together a diversity of scientific, technical and community interests to discuss current opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV and other populations, discussing implementation challenges to achieve elimination of hepatitis B and C in Latin America and worldwide.

5th International HIV/viral hepatitis co-infection meeting: viral hepatitis elimination in Latin America and globally: how close are we?

Sunday 21 July, 14:45–16:45, Palacio de Valparaíso 1
The meeting will provide a unique opportunity to bring together a diversity of scientific, technical and community interests to discuss current opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV and other populations, discussing implementation challenges to achieve elimination of hepatitis B and C in Latin America and worldwide.

5th HIV-Exposed Uninfected (HEU) Child and Adolescent Workshop

Sunday 21 July
The workshop provides the only international annual forum for dialogue and discussion among the community of clinicians, scientists, epidemiologists, public health and policy experts, families living with HIV and advocates concerned about the short-, medium- and long-term well-being of HEU children and adolescents.

Achieving 90-90-90 and “getting to zero” in the Americas requires addressing equity for indigenous communities (SUSA06)

Sunday 21 July, 10:15–12:15, Palacio de Iturbide 3
This satellite presents current evidence of burden of diseases in indigenous peoples in the Americas, as well as epidemic drivers and social determinants. Representatives from indigenous organizations will discuss and propose strategies to ensure and expand access to culturally sensitive and acceptable comprehensive prevention, care and treatment services. Co-organized with UNAIDS, the International Indigenous Working Group on HIV/AIDS -IWGHA, and the Secretariado Internacional de Pueblos Indígenas frente al VIH/sida, la sexualidad y los Derechos Humanos - SIPIA, and International Secretariat of Indigenous Peoples on HIV/AIDS, sexuality and Human Rights.

PrEP and STIs: opportunities and challenges (SUSA07)

Sunday 21 July, 12:30–14:30, Palacio de Valparaíso 1
As PrEP services expand, there has been growing need for STI services and recognition that PrEP can serve as a gateway to sexual health services for key populations.

One year on: updated WHO guidelines on first-line treatment for people living with HIV (SUSA13)

Sunday 21 July, 14:45–16:45, Palacio de Valparaíso 1
This satellite will review the status of safety and efficacy of DTG based antiretroviral (ARV) regimens, including the basic science models, pregnancy cohorts, clinical trial evidence, risk benefit modelling and community values and preferences that fed into updated recommendations. WHO will present 2019 guidelines on first-line and second-line ARV regimens, a new app on HIV treatment, and the 2019 HIV Drug resistance report.

New generations free of HIV, syphilis and hepatitis B: adding hepatitis B to the global initiative of elimination of mother-to-child transmission of HIV and syphilis (SUSA16)

Sunday 21 July, 14:45–16:45, Casa del Diezmo 3 y 4
Leveraging on the experience to achieve dual elimination of mother-to-child transmission (EMTCT) of HIV and syphilis, work is underway to eliminate other infectious diseases through the maternal-child health platform. The satellite will disseminate reviews on the new phase of EMTCT work, particularly focusing on the elimination of perinatal and early childhood hepatitis B.

It’s time for PrEP in Latin America and the Caribbean! (SUSA23)

Sunday 21 July, 17:00–19:00, Casa del Diezmo 3 and 4
This satellite will include the launch of the new WHO technical brief on event-driven pre-exposure prophylaxis (PrEP) and will showcase country experiences and regional initiatives in Latin American and the Caribbean to advance PrEP implementation within HIV combination prevention strategies with focus on key populations.
This satellite will highlight the need to address quality gaps within HIV programmes, share WHO guidance on strengthening quality of HIV services, country experiences in implementation of national quality strategies, and community perspectives on demand-side actions to support quality care.

**Addressing the quality gap within HIV programmes: improving clinical outcomes and preventing HIV drug resistance (MOSA01)**

**Monday 22 July, 07:00-08:30, Palacio de Iturbide 1 y 2**

This satellite will highlight the need to address quality gaps within HIV programmes, share WHO guidance on strengthening quality of HIV services, country experiences in implementation of national quality strategies, and community perspectives on demand-side actions to support quality care.

**Strategies towards integrating point-of-care (POC) testing quality assurance (QA) into existing quality assurance programs (MOSA03)**

**Monday 22 July, 07:00-08:30, Casa del Diezmo 3 y 4**

This satellite session seeks to create awareness and outline key elements to consider for the integration of POC testing such as those using automated closed systems into national QA programs. It’s of interest to government officials, national HIV & diagnostics program managers, implementing partners, clinicians and laboratory technologists, civil society and people living with HIV.

**Towards zero new HIV infections: Lessons learnt from the HPTN 071 (PopART) trial (MOSY03)**

**Monday 22 July, 11:00 - 12:30, Palacio de Valparaíso 1**

WHO will participate in the session to discuss important outcomes of the study to be considered to understand the results and to inform policy and implementation.

**What’s new in diagnostics: novel HIV molecular interventions to support expansion of viral load access (MOSA10)**

**Monday 22 July, 18:30–20:30, Casa del Diezmo 3 y 4**

In this Satellite, ASLM, WHO and partners will present new and tried concepts for scaling up HIV viral load testing across settings. These concepts form a newly developed implementation document to be launched during the session.

**New approaches to monitor HIV services and accelerate the response to HIV among men who have sex with men (MSM) and transgender women in Latin America (MOSA07)**

**Monday 22 July, 18:30–20:30, Palacio de Valparaíso 1**

This satellite is co-organized with the Ibero-American Network on Men Who Have Sex with Men and Trans Studies (RIGHT) and Coalition Plus. It will present new initiatives, regional research networks and country experiences on monitoring HIV services and needs for MSM and transgender women in Latin America.

**WHO response to the results of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) study (TUSA01)**

**Tuesday 23 July, 07:30–08:30, Casa del Diezmo 1 y 2**

This session highlights several aspects of the WHO response showing the process, challenges and considerations.

**The power of partners! Positively engaging networks of people with HIV in testing, treatment and prevention (TUSA08)**

**Tuesday 23 July, 18:30 - 20:30 Casa del Diezmo 1 y 2**

This satellite will disseminate key lessons learned from programs implementing HIV partner notification services globally, including high impact articles from a JIAS supplement to be launched.

**Breaking barriers: Innovative, differentiated HIV services and self-care options for men (TUSA05)**

**Tuesday 23 July, 18:30 - 20:30, Palacio de Valparaíso 2**

This session highlights lessons from HIV programmes overcoming barriers to male uptake, including involving men in designing services that are adapted to serve them across their lifespans.

**Urine LAM tests: A golden opportunity to end TB deaths among people with advanced HIV (TUSA10)**

**Tuesday 23 July, 18:30 - 20:30, Casa Montejo 1**

This session will share the latest evidence on these diagnostic tests, providing update on new WHO guidelines, review the reasons behind poor policy uptake by countries, and share best practice and advocacy efforts by civil society to promote LAM uptake.
Key sessions

**Going online to accelerate the end of AIDS (TUSA11)**

Tuesday 23, 2019, 18:30-20:30, Palacio de Iturbide 3

This satellite session will offer a vision for safely and effectively using online and mobile platforms to accelerate progress toward epidemic control, particularly among key populations.

**HIV outbreaks and responses: lessons applied**

Wednesday, 24 July, 14:30-16:30, Venue TBC

IAS, WHO and country experts will present on the recent HIV outbreaks from Pakistan, Cambodia and Indiana, USA. The science behind the outbreak investigation and the response will be shared; use of phylogenetic analysis and field epidemiology will be explored to guide approaches to better anticipate, prevent and rapidly address future HIV and other blood-borne infectious disease outbreaks.

**Political will to getting to zero infections (WESY06)**

Wednesday 24 July, 16:30 - 18:00, Sala A

This session aims to reflect on and determine the importance of political will in getting to zero new infections; draw lessons from past successes of the HIV response that catapulted it and maintained high-level political commitment for two decades; provoke discussions on how to maintain high levels of political will at a global level and within countries for HIV in the face of emerging transitions and competing priorities.
Press conferences

Press conference on dolutegratir issues

Monday, 22 July, 10:00-10:45
Press Conference Room/ Casa Montejo 3

DR MEG DOHERTY
Coordinator, Treatment and Care, Department of HIV, WHO

Briefing for Spanish-speaking media

Tuesday, 23 July, 11:30-12:30
Press Conference Room/ Casa Montejo 3

DR MASSIMO GHIDINELLI
Chief, Unit of HIV, hepatitis, TB and Sexually transmitted infections, PAHO/WHO
<table>
<thead>
<tr>
<th>WHO at IAS2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implementing an indeterminate range for more accurate early infant diagnosis: 2018 WHO recommendations (MOPEB122)</td>
</tr>
<tr>
<td>A meta-analysis of using dried blood spots for HIV viral load testing with lower treatment failure thresholds (MOPEB133)</td>
</tr>
<tr>
<td>Adoption of 2018 WHO recommendations on preferred first line antiretroviral therapy (MOPEB232)</td>
</tr>
<tr>
<td>Comparing low-dose efavirenz to standard-dose efavirenz and dolutegravir: A systematic review and network metanalysis (MOPEB233)</td>
</tr>
<tr>
<td>Differentiated ART delivery for key populations: a systematic review (MOPED532)</td>
</tr>
<tr>
<td>Who self-reports never-testing for HIV after community-based distribution of HIV self-testing kits in Malawi, Zambia and Zimbabwe? (MOPED587)</td>
</tr>
<tr>
<td>Too much of a good thing? Prevalence and determinants of frequent HIV testing in Zambia and Malawi (MOPED590)</td>
</tr>
<tr>
<td>Mapping the need and benefit of PrEP in three African countries to estimate programmatic targets (TUPEC441)</td>
</tr>
<tr>
<td>Retesting for HIV on antiretroviral therapy (ART) against policy recommendations: investigating the impact on sensitivity of self-testing, Blantyre, Malawi (TUPEC448)</td>
</tr>
<tr>
<td>Value of secondary distribution of HIV self-test kits to male partners of female sex workers (TUPEC452)</td>
</tr>
<tr>
<td>Value of secondary distribution of HIV self-test kits to male partners of women attending antenatal clinics (TUPEC453)</td>
</tr>
<tr>
<td>Uptake and performance of blood-based self-testing versus oral fluid-based self-testing in Blantyre district, Malawi (TUPED669)</td>
</tr>
<tr>
<td>Does the use of HIV self-testing kits lead to unintended effects? Evidence from female sex workers in Malawi (WEAC0201)</td>
</tr>
<tr>
<td>Self-testing: Going the final mile Community-led HIV self-testing, with and without assistance, successfully reaches key populations and their partners in Viet Nam (WEAC0204)</td>
</tr>
<tr>
<td>Community-led delivery of HIV self-testing targeting adolescents and men in rural Malawi: a cluster-randomised trial.</td>
</tr>
</tbody>
</table>
**WHO at IAS2019**

**New publications**

- **Policy brief**
  WHO updated recommendations on first- and second-line antiretroviral regimens for treating and preventing HIV infection, July 2019

- **New App**
  WHO HIV Tx app 2019

- **New report**
  2019 HIV drug resistance report

- **Technical brief**
  What’s the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO’s recommendation on oral PrEP

- **Policy brief**
  Maintaining and improving quality of care within HIV clinical services

- **Policy brief**
  The prevention and control of sexually transmitted infections (STIs), in the era of oral pre-exposure prophylaxis (PrEP) for HIV

- **Fact sheet**
  on WHO HIV policy adoption and implementation, 2019

- **Progress report**
  on HIV, viral hepatitis and sexually transmitted infections 2019

**JIAS supplement**

“The power of partners: Experiences from implementing and scaling-up HIV partner notification and index testing services”

**New toolkit**

HIV molecular diagnostics toolkit to improve access to viral load and infant diagnosis

**New Training material**

JHPIEGO/PAHO/WHO PrEP e-learning package in English and Spanish
More information

www.who.int/hiv/  www.who.int/hepatitis/